Title:
PROSTATE-SPECIFIC TUMOR ANTIGEN AND USES THEREOF
Document Type and Number:
WIPO Patent Application WO/2014/047085
Kind Code:
A3
Abstract:
Twenty-one PSGR-derived peptides predicted by an immuno-informatics approach based on the HLA-A2 binding motif were examined for their ability to induce peptide-specific T cell responses in peripheral blood mononuclear cells (PBMCs) obtained from either HLA-A2+ healthy donors or HLA-A2+ prostate cancer patients. The recognition of HLA-A2 positive and PSGR expressing LNCaP cells was also tested. Three peptides, PSGR3, PSGR4 and PSGR14 frequently induced peptide-specific T cell responses in PBMCs from both healthy donors and prostate cancer patients, and are recognized by CD8+ T cells in an HLA-A2 dependent manner. These peptide-specific T cells recognize HLA-A2+ and PSGR+ tumor cells, and killed LNCaP prostate cancer cells in an HLA class I-restricted manner. These PSGR-derived peptides identified are useful as diagnostic markers as well as immune targets for anticancer vaccines.
Inventors:
WANG RONGFU (US)
Application Number:
PCT/US2013/060254
Publication Date:
July 23, 2015
Filing Date:
September 18, 2013
Export Citation:
Assignee:
WANG RONGFU (US)
International Classes:
A61K39/00; A61P35/00
Domestic Patent References:
| WO2012006634A2 | 2012-01-12 |
Foreign References:
| US20060263342A1 | 2006-11-23 | |||
| US20090217401A1 | 2009-08-27 | |||
| US20090191185A1 | 2009-07-30 |
Attorney, Agent or Firm:
LI, Kening (150 West Jefferson Suite 250, Detroit MI, US)
Download PDF:
Previous Patent: GESTURE-INITIATED KEYBOARD FUNCTIONS
Next Patent: IMAGE CAPTURE-BASED PREDICTIVE CONTROL DEVICE
Next Patent: IMAGE CAPTURE-BASED PREDICTIVE CONTROL DEVICE